1,105 results on '"Borer, Jeffrey S"'
Search Results
2. Effect of Left Ventricular Conduction Delay on All-Cause and Cardiovascular Mortality (from the PRECISION Trial)
3. Sample Size Requirements for Clinical Trials of Transcatheter Valve Replacement and Valve Repair Devices
4. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen
5. Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes
6. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial
7. Efficacy of ivabradine in heart failure patients with a high‐risk profile (analysis from the SHIFT trial).
8. Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure Study
9. Medical Misinformation: Vet the Message!
10. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease
11. How to Prepare a Scientific Paper
12. Misconceptions and Facts About Mitral Regurgitation
13. Update on ivabradine for heart failure
14. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial)
15. Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction
16. Meta-Analysis of the Relation of Body Mass Index to All-Cause and Cardiovascular Mortality and Hospitalization in Patients With Chronic Heart Failure
17. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model
18. Resting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease
19. Surgical Treatment of Ischemic Mitral Regurgitation: Valve Repair Versus Replacement
20. Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates
21. Efficacy and Safety of Ivabradine in Patients With Severe Chronic Systolic Heart Failure (from the SHIFT Study)
22. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT
23. Impact of Beta-Blockade on Cardiac Events in Patients with Chronic Severe Nonischemic Mitral Regurgitation
24. Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure
25. Abstract 18347: Prognostic Significance of Activation Delay by Cross Correlation Analysis Using Tissue Doppler Imaging in Patients With Heart Failure and Narrow QRS Duration; an Echocardiography Guided Cardiac Resynchronization Therapy (Echo-CRT) Trial Substudy of Patients Not Randomized to CRT
26. Abstract 15937: Abnormal Left Ventricular Conduction is Associated With Increased Cardiovascular Mortality Compared to Abnormal Right Ventricular or Normal Conduction: Insights From the Precision Trial
27. Abstract 14007: Advancing Age is a Stronger Predictor of Increasing Valvular Heart Disease Hospitalizations Than Variations in Gender, Race or Ethnicity
28. Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients
29. Usefulness of Preoperative Exercise Tolerance to Predict Late Survival and Symptom Persistence After Surgery for Chronic Nonischemic Mitral Regurgitation
30. First-pass and Equilibrium Radionuclide Angiography
31. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris
32. Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT
33. Pathophysiology of Heart Failure in Regurgitant Valvular Diseases: Relation to Ventricular Dysfunction and Clinical Debility
34. Challenges to Data Monitoring Committees When Regulatory Authorities Intervene
35. Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial
36. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial
37. Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations
38. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
39. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
40. Efficacy of Ivabradine, a Selective If Inhibitor, in Patients With Chronic Stable Angina Pectoris and Diabetes Mellitus
41. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial
42. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium
43. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population
44. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy
45. Acceptability and Psychometric Properties of the Minnesota Living With Heart Failure Questionnaire Among Patients Undergoing Heart Valve Surgery: Validation and Comparison With SF-36
46. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
47. Relation of Indirect Vasodilator Use to Prognosis in Patients with Chronic Severe Mitral Regurgitation
48. Role of Oral Factor Xa Inhibitors after Acute Coronary Syndrome
49. Trials of implantable monitoring devices in heart failure: which design is optimal?
50. Heart rate reduction in cardiovascular disease and therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.